EAST RUTHERFORD, N.J., Sept. 26, 2017 (GLOBE NEWSWIRE) -- Cambrex Corporation (NYSE:CBM), the leading manufacturer of small molecule innovator and generic Active Pharmaceutical Ingredients (APIs), ...

Wilmington PharmaTech, a CRDMO specializing in complex, custom active pharmaceutical ingredients (APIs) for small molecules, ...

China and India, which are the largest producers of APIs for the U.S. drug supply, also account for most of the FDA regulatory actions. Not only do quality problems at Chinese and Indian firms raise ...

Eli Lilly and Company (Lilly) plans to construct an active pharmaceutical ingredient (API) manufacturing facility, totaling around 1 million square feet, in Harris County, Texas. According to news ...

EAST RUTHERFORD, N.J., Oct. 22, 2025 /PRNewswire/ -- Cambrex, a leading global contract development and manufacturing organization (CDMO), today announced a $120 million investment to expand its U.S.

QINGDAO, CHINA, January 19, 2026 /EINPresswire.com/ — As the pharmaceutical industry continues to evolve in the wake of pandemic-driven disruptions and heightened ...

The global industry was valued at US$ 38.9 Bn in 2022 and is expected to register a CAGR of 7.1% from 2023 to 2031. Demand for biologics, biosimilars, and other biopharmaceuticals is growing at a ...

Pakistan’s pharmaceutical manufacturing industry is one of the country’s largest and fastest growing industries. It includes more than 650 manufacturers and accounts for approximately Rs. 748 billion ...